New drug under watch: korean study tracks Real-World safety
NCT ID NCT07416162
Summary
This study aims to monitor the safety and effectiveness of the drug Iptacopan (Fabhalta®) in real-world medical settings in Korea. It will follow about 21 adult patients who have been diagnosed with either Paroxysmal Nocturnal Hemoglobinuria (PNH, a rare blood disease) or C3 Glomerulopathy (C3G, a rare kidney disease) and are taking the drug as prescribed. The main goal is to track any side effects and see how well the drug works in controlling these conditions outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.